Skip to main content
Top
Published in: Current HIV/AIDS Reports 2/2015

01-06-2015 | Central Nervous System and Cognition (SS Spudich, Section Editor)

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

Authors: Francesca Ferretti, Magnus Gisslen, Paola Cinque, Richard W. Price

Published in: Current HIV/AIDS Reports | Issue 2/2015

Login to get access

Abstract

CNS infection is a nearly constant facet of systemic CNS infection and is generally well controlled by suppressive systemic antiretroviral therapy (ART). However, there are instances when HIV can be detected in the cerebrospinal fluid (CSF) despite suppression of plasma viruses below the clinical limits of measurement. We review three types of CSF viral escape: asymptomatic, neuro-symptomatic, and secondary. The first, asymptomatic CSF escape, is seemingly benign and characterized by lack of discernable neurological deterioration or subsequent CNS disease progression. Neuro-symptomatic CSF escape is an uncommon, but important, entity characterized by new or progressive CNS disease that is critical to recognize clinically because of its management implications. Finally, secondary CSF escape, which may be even more uncommon, is defined by an increase of CSF HIV replication in association with a concomitant non-HIV infection, as a consequence of the local inflammatory response. Understanding these CSF escape settings not only is important for clinical diagnosis and management but also may provide insight into the CNS HIV reservoir.
Literature
2.
go back to reference Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2000;30(6):962–5. doi:10.1086/313810.CrossRef Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2000;30(6):962–5. doi:10.​1086/​313810.CrossRef
3.
go back to reference Enting RH, Prins JM, Jurriaans S, Brinkman K, Portegies P, Lange JM. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32(7):1095–9. doi:10.1086/319602.CrossRef Enting RH, Prins JM, Jurriaans S, Brinkman K, Portegies P, Lange JM. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32(7):1095–9. doi:10.​1086/​319602.CrossRef
4.
go back to reference Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagra RM, Russell JJ, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol Off Publ Int Retrovirol Assoc. 1995;10(4):425–35.CrossRef Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagra RM, Russell JJ, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol Off Publ Int Retrovirol Assoc. 1995;10(4):425–35.CrossRef
5.
go back to reference Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol. 1992;30(7):1768–71.PubMedCentralPubMed Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol. 1992;30(7):1768–71.PubMedCentralPubMed
6.
go back to reference Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS. 1998;12(4):389–94.CrossRefPubMed Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS. 1998;12(4):389–94.CrossRefPubMed
7.
go back to reference Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13(9):1051–61.CrossRefPubMed Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13(9):1051–61.CrossRefPubMed
8.
go back to reference Yilmaz A, Svennerholm B, Hagberg L, Gisslen M. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther. 2006;11(7):833–7.PubMed Yilmaz A, Svennerholm B, Hagberg L, Gisslen M. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther. 2006;11(7):833–7.PubMed
11.
go back to reference Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21(4):271–6.CrossRefPubMed Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21(4):271–6.CrossRefPubMed
13.
go back to reference Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev. 2013;15(3):152–61.PubMed Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev. 2013;15(3):152–61.PubMed
16.
go back to reference Karlsson U, Antonsson L, Ljungberg B, Medstrand P, Esbjornsson J, Jansson M, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS. 2012;26(14):1739–44. doi:10.1097/QAD.0b013e3283560791.CrossRefPubMed Karlsson U, Antonsson L, Ljungberg B, Medstrand P, Esbjornsson J, Jansson M, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS. 2012;26(14):1739–44. doi:10.​1097/​QAD.​0b013e3283560791​.CrossRefPubMed
18.
go back to reference Maslin CL, Kedzierska K, Webster NL, Muller WA, Crowe SM. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005;3(4):303–17.CrossRefPubMed Maslin CL, Kedzierska K, Webster NL, Muller WA, Crowe SM. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005;3(4):303–17.CrossRefPubMed
19.
go back to reference Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol. 1996;156(3):1284–95.PubMed Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol. 1996;156(3):1284–95.PubMed
23.
go back to reference del Saz SV, Sued O, Falco V, Aguero F, Crespo M, Pumarola T, et al. Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol. 2008;14(6):474–9. doi:10.1080/13550280802195367.CrossRefPubMed del Saz SV, Sued O, Falco V, Aguero F, Crespo M, Pumarola T, et al. Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol. 2008;14(6):474–9. doi:10.​1080/​1355028080219536​7.CrossRefPubMed
25.
go back to reference Soulie C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr. 2009;51(1):60–4. doi:10.1097/QAI.0b013e31819fb903.CrossRefPubMed Soulie C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr. 2009;51(1):60–4. doi:10.​1097/​QAI.​0b013e31819fb903​.CrossRefPubMed
26.
go back to reference Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191(6):890–8. doi:10.1086/428095.CrossRefPubMed Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191(6):890–8. doi:10.​1086/​428095.CrossRefPubMed
27.
go back to reference Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, Andreis S, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol. 2011;49(4):1441–5. doi:10.1128/JCM. 02564-10.CrossRefPubMedCentralPubMed Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, Andreis S, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol. 2011;49(4):1441–5. doi:10.​1128/​JCM.​ 02564-10.CrossRefPubMedCentralPubMed
28.
go back to reference Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O’Connor MJ, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73(1):205–13.PubMedCentralPubMed Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O’Connor MJ, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73(1):205–13.PubMedCentralPubMed
30.
go back to reference Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089–93.CrossRefPubMed Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089–93.CrossRefPubMed
31.
go back to reference Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175(2):434–7.CrossRefPubMed Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175(2):434–7.CrossRefPubMed
32.
go back to reference Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194(12):1686–96. doi:10.1086/508750.CrossRefPubMed Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194(12):1686–96. doi:10.​1086/​508750.CrossRefPubMed
33.
go back to reference Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36(1):562–6.CrossRefPubMed Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36(1):562–6.CrossRefPubMed
34.
go back to reference Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, et al. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003;61(10):1391–6.CrossRefPubMed Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, et al. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003;61(10):1391–6.CrossRefPubMed
35.
go back to reference Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54(4):927–36.CrossRefPubMed Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54(4):927–36.CrossRefPubMed
37.
go back to reference Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir. 2001;17(5):377–83. doi:10.1089/088922201750102409.CrossRefPubMed Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir. 2001;17(5):377–83. doi:10.​1089/​0889222017501024​09.CrossRefPubMed
38.
go back to reference Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–8. doi:10.1097/QAD.0000000000000400.CrossRefPubMed Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–8. doi:10.​1097/​QAD.​0000000000000400​.CrossRefPubMed
40.
go back to reference Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med Publ Int AIDS Soc, USA. 2010;18(2):45–55. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med Publ Int AIDS Soc, USA. 2010;18(2):45–55.
42.
go back to reference Croteau D, Rossi SS, Best BM, Capparelli E, Ellis RJ, Clifford DB, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90 % inhibitory concentration. J Antimicrob Chemother. 2013;68(3):684–9. doi:10.1093/jac/dks441.CrossRefPubMedCentralPubMed Croteau D, Rossi SS, Best BM, Capparelli E, Ellis RJ, Clifford DB, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90 % inhibitory concentration. J Antimicrob Chemother. 2013;68(3):684–9. doi:10.​1093/​jac/​dks441.CrossRefPubMedCentralPubMed
44.
go back to reference Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(7):1032–7. doi:10.1093/cid/ciu477.CrossRef Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(7):1032–7. doi:10.​1093/​cid/​ciu477.CrossRef
45.•
go back to reference Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–25. doi:10.1086/657342. Shows the proportion of asymptomatic CSF viral escape in a group of ART-treated patients with suppressed systemic HIV replication. It also shows the association between CSF viral escape and intrathecal immune activation. CrossRefPubMedCentralPubMed Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–25. doi:10.​1086/​657342. Shows the proportion of asymptomatic CSF viral escape in a group of ART-treated patients with suppressed systemic HIV replication. It also shows the association between CSF viral escape and intrathecal immune activation. CrossRefPubMedCentralPubMed
46.
go back to reference Edén A AL, Fuchs D, Hagberg L, Nilsson S, Svennerholm B, Yilmaz A, Zetterberg H, Gisslén M. Cerebrospinal fluid viral blips and persistent escape in HIV-infected patients on ART. Topics in antiviral medicine. 2014;22(2):(e–1):210. Edén A AL, Fuchs D, Hagberg L, Nilsson S, Svennerholm B, Yilmaz A, Zetterberg H, Gisslén M. Cerebrospinal fluid viral blips and persistent escape in HIV-infected patients on ART. Topics in antiviral medicine. 2014;22(2):(e–1):210.
47.
go back to reference Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–8. doi:10.1038/nm880.CrossRefPubMed Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–8. doi:10.​1038/​nm880.CrossRefPubMed
48.
go back to reference Imaz A, Cayuela N, Niubo J, Tiraboschi JM, Izquierdo C, Cabellos C, et al. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir. 2014;30(10):984–7. doi:10.1089/AID.2014.0014.CrossRefPubMed Imaz A, Cayuela N, Niubo J, Tiraboschi JM, Izquierdo C, Cabellos C, et al. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir. 2014;30(10):984–7. doi:10.​1089/​AID.​2014.​0014.CrossRefPubMed
49.•
go back to reference Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24(15):2347–54. doi:10.1097/QAD.0b013e32833db9a1. Reports rebounds of HIV replication in CSF in association with neurological disease in patients failing a LPV/r monotherapy within a randomized clinical trial.PubMed Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24(15):2347–54. doi:10.​1097/​QAD.​0b013e32833db9a1​. Reports rebounds of HIV replication in CSF in association with neurological disease in patients failing a LPV/r monotherapy within a randomized clinical trial.PubMed
50.
51.
go back to reference Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, et al. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk? Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(11):1655–6. doi:10.1093/cid/ciu679.CrossRef Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, et al. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk? Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(11):1655–6. doi:10.​1093/​cid/​ciu679.CrossRef
52.
go back to reference Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–74. doi:10.1097/QAD.0b013e32833dec20.PubMed Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–74. doi:10.​1097/​QAD.​0b013e32833dec20​.PubMed
53.
55.
go back to reference Estebanez M, Stella-Ascariz N, Mingorance J, Perez-Valero I, Gonzalez-Baeza A, Bayon C, et al. A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(4):419–23. doi:10.1097/QAI.0000000000000337.CrossRefPubMed Estebanez M, Stella-Ascariz N, Mingorance J, Perez-Valero I, Gonzalez-Baeza A, Bayon C, et al. A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(4):419–23. doi:10.​1097/​QAI.​0000000000000337​.CrossRefPubMed
56.
go back to reference Ferretti F, Gianotti N, Lazzarin A, Cinque P. Central nervous system HIV infection in “less-drug regimen” antiretroviral therapy simplification strategies. Semin Neurol. 2014;34(1):78–88. doi:10.1055/s-0034-1372345.CrossRefPubMed Ferretti F, Gianotti N, Lazzarin A, Cinque P. Central nervous system HIV infection in “less-drug regimen” antiretroviral therapy simplification strategies. Semin Neurol. 2014;34(1):78–88. doi:10.​1055/​s-0034-1372345.CrossRefPubMed
57.••
go back to reference Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(5):773–8. doi:10.1086/650538. The first published series of cases of symptomatic CSF viral escape.CrossRef Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(5):773–8. doi:10.​1086/​650538. The first published series of cases of symptomatic CSF viral escape.CrossRef
58.••
go back to reference Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765–74. doi:10.1097/QAD.0b013e328355e6b2. An additional detailed series of cases of symptomatic CSF viral escape.CrossRefPubMed Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765–74. doi:10.​1097/​QAD.​0b013e328355e6b2​. An additional detailed series of cases of symptomatic CSF viral escape.CrossRefPubMed
62.
go back to reference Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26(13):1726–8. doi:10.1097/QAD.0b013e32835646fb.CrossRefPubMed Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26(13):1726–8. doi:10.​1097/​QAD.​0b013e32835646fb​.CrossRefPubMed
63.
go back to reference Tamarit Mdel P, Quereda C, Gonzalez-Rozas M, Corral I, Casado JL. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retrovir. 2012;28(1):83–6. doi:10.1089/AID.2011.0020.CrossRefPubMed Tamarit Mdel P, Quereda C, Gonzalez-Rozas M, Corral I, Casado JL. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retrovir. 2012;28(1):83–6. doi:10.​1089/​AID.​2011.​0020.CrossRefPubMed
64.
go back to reference van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(3):387–90. doi:10.1086/649874.CrossRef van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(3):387–90. doi:10.​1086/​649874.CrossRef
65.
go back to reference Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;37(8):1107–11. doi:10.1086/378300.CrossRef Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;37(8):1107–11. doi:10.​1086/​378300.CrossRef
68.••
go back to reference Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol. 2013;23(5):525–33. doi:10.1111/bpa.12038. Detailed neuropathological description of cases with CD8+ cell encephalitis.CrossRefPubMed Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol. 2013;23(5):525–33. doi:10.​1111/​bpa.​12038. Detailed neuropathological description of cases with CD8+ cell encephalitis.CrossRefPubMed
69.
go back to reference Lescure FX, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(1):101–8. doi:10.1093/cid/cit175.CrossRef Lescure FX, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(1):101–8. doi:10.​1093/​cid/​cit175.CrossRef
70.••
go back to reference Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16(7):1019–29. Detailed neuropathological description of HIV leukoencephalitis cases observed in the early ART era, mostly associated with systemic virological failure and characterized by brain inflammation.CrossRefPubMedCentralPubMed Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16(7):1019–29. Detailed neuropathological description of HIV leukoencephalitis cases observed in the early ART era, mostly associated with systemic virological failure and characterized by brain inflammation.CrossRefPubMedCentralPubMed
72.
go back to reference Moling O, Rossi P, Rimenti G, Vedovelli C, Mian P. Varicella-zoster virus meningitis and cerebrospinal fluid HIV RNA. Scand J Infect Dis. 2001;33(5):398–9.CrossRefPubMed Moling O, Rossi P, Rimenti G, Vedovelli C, Mian P. Varicella-zoster virus meningitis and cerebrospinal fluid HIV RNA. Scand J Infect Dis. 2001;33(5):398–9.CrossRefPubMed
73.
go back to reference Falcone EL, Adegbulugbe AA, Sheikh V, Imamichi H, Dewar RL, Hammoud DA, et al. Cerebrospinal fluid HIV-1 compartmentalization in a patient with AIDS and acute varicella-zoster virus meningomyeloradiculitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(5):e135–42. doi:10.1093/cid/cit356.CrossRef Falcone EL, Adegbulugbe AA, Sheikh V, Imamichi H, Dewar RL, Hammoud DA, et al. Cerebrospinal fluid HIV-1 compartmentalization in a patient with AIDS and acute varicella-zoster virus meningomyeloradiculitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(5):e135–42. doi:10.​1093/​cid/​cit356.CrossRef
Metadata
Title
Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy
Authors
Francesca Ferretti
Magnus Gisslen
Paola Cinque
Richard W. Price
Publication date
01-06-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 2/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0267-7

Other articles of this Issue 2/2015

Current HIV/AIDS Reports 2/2015 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

Quality of Care and Service Expansion for HIV Care and Treatment

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.